When the cumulative dose poisons the endothelium
Gemcitabine and mitomycin thrombotic microangiopathy
Two old cytotoxics — mitomycin and gemcitabine — injure the microvascular endothelium directly and in proportion to the cumulative dose, so months into therapy the small vessels clot, red cells shear, platelets fall, and the kidney fails: a dose-dependent thrombotic microangiopathy that is not TTP, does not respond to plasma exchange, and is answered first by stopping the drug.
- 0.31%
- gemcitabine TMA incidenceCumulative incidence of gemcitabine-associated TMA (8 of 2,586 patients) in the largest single-institution series — higher than the long-quoted 0.015%
- 8 months
- median onset (gemcitabine)Median time from starting gemcitabine to TMA (range 3–18 months) at cumulative doses of 9–56 g/m² — a dose-cumulative toxicity, not an early idiosyncratic reaction
- 4–15%
- HUS risk with mitomycinEstimated risk of cancer-associated hemolytic-uremic syndrome after mitomycin — cumulative dose exceeded 60 mg in all but 9 of 85 national-registry cases
- >50%
- mortality (mitomycin registry)Share of the 85 registry patients who died of or with the syndrome, most within 8 weeks; conventional treatment was largely ineffective
- 20,000 mg/m²
- median cumulative doseMedian cumulative gemcitabine dose at HUS onset across a 26-case review; 11 of 23 with a known outcome died within weeks
Teaching case · illustrative composite, not a real patient
A 61-year-old woman with metastatic pancreatic adenocarcinoma, about seven months and many cycles into gemcitabine, develops new hypertension (158/98, previously normal) over a few weeks. Labs then show hemoglobin falling to 7.8 g/dL with schistocytes on the film, an LDH of 640 U/L with an undetectable haptoglobin, platelets of 62,000, and a creatinine risen from 0.8 to 2.6 mg/dL with new proteinuria.
The microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury in a patient deep into gemcitabine point to gemcitabine-induced thrombotic microangiopathy. ADAMTS13 activity is not severely deficient, arguing against TTP; there is no diarrheal prodrome. Gemcitabine is stopped permanently. Blood pressure is controlled, transfusion is used sparingly (transfusions have preceded noncardiogenic pulmonary edema in these patients), and supportive care — including dialysis if needed — is given. Plasma exchange, often tried, is of limited benefit in this dose-dependent TMA. Hematologic parameters stabilize over weeks; renal recovery is partial. When effective tumor control later requires it, rechallenge is considered only under prophylactic terminal-complement blockade.
Teaching point — Gemcitabine and mitomycin cause a dose-cumulative thrombotic microangiopathy that is mechanistically distinct from both TTP (this is not ADAMTS13-deficient) and the VEGF-inhibitor TMA (which is a glomerular-restricted VEGF-withdrawal lesion): here the drug poisons the endothelium directly, so the syndrome emerges months in, after a substantial cumulative dose. New or worsening hypertension can herald it by weeks. The first and most important intervention is permanent discontinuation of the culprit — plasma exchange generally does not work — with BP control, cautious transfusion, and dialysis as supportive measures. Terminal complement blockade (eculizumab) is emerging for refractory disease and to enable rechallenge.
How it happens
The pathophysiology as a cascade — select a step to follow the mechanism.
How we learned it
- 1989
Lesesne and colleagues analyze 85 national-registry cases of cancer-associated hemolytic-uremic syndrome: mitomycin was in the regimen of 84, the cumulative dose exceeded 60 mg in all but 9, the risk after mitomycin was 4–15%, and over half died — most within 8 weeks.
Established mitomycin as the prototype dose-dependent chemotherapy TMA and quantified its lethality when conventional treatment was all that was available.
PMID 2497229 - 2002
Walter et al. assemble 26 reported cases of gemcitabine-associated HUS — median cumulative dose 20,000 mg/m², onset around 7 months — and show it is potentially fatal (11 of 23 with a known outcome died within weeks).
Characterized gemcitabine TMA as a real, dose-cumulative, and dangerous entity rather than an anecdote.
PMID 12324937 - 2004
Humphreys et al. report the largest single-institution gemcitabine-TMA series, raising the incidence estimate to 0.31% and identifying new or exacerbated hypertension as an early herald in 7 of 9 patients.
Moved the incidence upward from 0.015% and gave clinicians a practical early-warning sign — a rising blood pressure weeks before the full syndrome.
PMID 15197810 - 2015
Reese and colleagues apply systematic causality criteria across the Oklahoma and Wisconsin registries; gemcitabine emerges as one of only three drugs with definite evidence of causing TMA (alongside quinine and pentostatin).
Placed gemcitabine among the drugs with the strongest causal evidence — a dose-dependent toxic mechanism, distinct from the antibody-mediated TMA of quinine.
PMID 25639727 - 2025
Chewcharat et al. report using prophylactic eculizumab (terminal complement blockade) to rechallenge gemcitabine after GITMA, with no recurrence over four cycles.
Extended complement blockade from refractory treatment to secondary prevention, opening a path to continue an effective drug after TMA — though optimal dosing and timing remain undefined.
PMID 40825470
The landmark studies
Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry
Lesesne JB, et al. · J Clin Oncol 1989 · PMID 2497229
Mitomycin was implicated in nearly all cases in a clearly dose-dependent way, with high mortality and little response to conventional therapy — the defining description of cytotoxic-chemotherapy TMA.
Mitomycin in 84/85; cumulative dose >60 mg in all but 9; HUS risk after MMC 4–15%; mortality >50% (most within 8 wk); noncardiogenic pulmonary edema 65%
Gemcitabine-associated thrombotic microangiopathy
Humphreys BD, et al. · Cancer 2004 · PMID 15197810
Gemcitabine TMA is more common than the classic 0.015% estimate, arises after months of cumulative dosing, and is frequently heralded by new or worsening hypertension.
Incidence 0.31% (8/2,586); median onset 8 mo (3–18); cumulative dose 9–56 g/m²; new/exacerbated HTN 7/9; 2 required dialysis; no direct TMA deaths in this series
Drug-induced thrombotic microangiopathy: experience of the Oklahoma Registry and the BloodCenter of Wisconsin
Reese JA, et al. · Am J Hematol 2015 · PMID 25639727
Applying explicit evidence criteria, only a handful of drugs have a definite causal association with TMA; gemcitabine is one of them, reflecting a dose-dependent toxic (not antibody-mediated) mechanism.
51 patients across 5 drugs met the definite-association bar; gemcitabine, pentostatin, and quinine were the toxic/immune culprits; quinine accounted for 92% of the definite immune cases
Eculizumab prophylaxis for systematically rechallenging gemcitabine in gemcitabine-induced TMA
Chewcharat A, et al. · Am J Kidney Dis 2025 · PMID 40825470
Prophylactic terminal complement blockade allowed a patient with prior GITMA to resume gemcitabine without recurrence, supporting a complement contribution and a secondary-prevention strategy.
GITMA risk concentrates above a cumulative dose of 20,000 mg/m²; eculizumab 900 mg IV weekly ×4, then rechallenge; no recurrence over 4 cycles / 3 months
What the data says now
How disproportionately each agent's FAERS reports name these phenotypes vs. all other drugs (reporting odds ratio; significant signals only, 95% CI lower bound > 1; as of 2026-07-10). A reporting signal, not incidence or proven causation.
| Agent | TMA |
|---|---|
| Gemcitabine | Gemcitabine, Thrombotic Microangiopathy: ROR 26.00, 914 reports |
| Mitomycin C | Mitomycin C, Thrombotic Microangiopathy: ROR 23.34, 54 reports |
Median cumulative gemcitabine at onset
26-case literature review of gemcitabine HUS
PMID 12324937Median onset from gemcitabine start
Single-institution series (range 3–18 months)
PMID 15197810How it's managed
- 1
Recognize the triad — and the hypertension herald
Suspect it when microangiopathic hemolysis (schistocytes, high LDH, low haptoglobin), thrombocytopenia, and acute kidney injury appear in a patient months into gemcitabine or past a substantial cumulative mitomycin dose; new or worsening hypertension may precede the full picture by weeks and should trigger a blood film and platelet count.
Largest gemcitabine series — hypertension herald in 7/9, dose-cumulative onset · PMID 15197810
- 2
Stop the culprit drug — permanently
Immediate, permanent discontinuation of gemcitabine or mitomycin is the cornerstone. Supportive care follows: blood-pressure control, cautious transfusion (transfusions preceded noncardiogenic pulmonary edema in the registry), and dialysis as needed. Conventional therapy alone was largely ineffective in the historical cohorts.
National registry — conventional treatment ineffective; transfusion-associated pulmonary edema · PMID 2497229
- 3
Distinguish it from TTP and other TMAs
Check ADAMTS13 to exclude TTP — cytotoxic TMA is not severely ADAMTS13-deficient, so plasma exchange (the answer for TTP) is generally ineffective here. The cumulative-dose history, the timing, and the drug exposure identify the culprit; this is a dose-dependent toxic TMA, not an antibody-mediated one.
Systematic causality review — gemcitabine a definite, toxic-mechanism cause distinct from immune DITMA · PMID 25639727
- 4
Consider terminal complement blockade
Eculizumab has been used in refractory cytotoxic TMA and, prophylactically, to enable gemcitabine rechallenge without recurrence when an effective drug must be resumed; optimal dosing and timing are not yet defined.
Case report — eculizumab prophylaxis permitted uncomplicated gemcitabine rechallenge · PMID 40825470
What the guidelines say
Society and consensus recommendations addressing this syndrome, each with its key recommendation quoted verbatim.
Every citation on this page is a real, PubMed-verified reference. The teaching case is an illustrative composite, not a real patient. Medical-education content — not medical advice.